Patient's characteristics
| n=36 | ||
|---|---|---|
| Gender (M/F) | 27/9 | |
| Age (year) (Median) | 41 (18-85) | |
| Disease Duration (year) (Median) | 2.0 (0-20.3) | |
| Extent of Disease (%) | Extensive colitis | 21 (58.3) |
| Left-sided type | 13 (36.1) | |
| Proctitis | 2 (5.6) | |
| Clinical Course (%) | Initial attack type | 8 (22.2) |
| Chronic active type | 13 (36.1) | |
| Chronic intermittent type | 11 (30.6) | |
| Acute severe type | 4 (11.1) | |
| Clinical Activity score (Median) | 6 (5-16) | |
| Endoscopic Mayo score (Median) | 2 (2-3) | |
| CRP (mg/dl) (Median) | 0.58 (0.02-13.44) | |
| Medication at initiating SASP treatment (%) | Sustained release mesalazine | 9 (25.0) |
| Delayed release mesalazine | 27 (75.0) | |
| Enema foam | 14 (38.9) | |
| Corticosteroid | 2 (5.6) | |
| Thiopurine | 10 (27.8) | |
| GMAA | 4 (11.1) | |
| Tacrolimus | 4 (11.1) | |
| Anti TNF-α agent | 6 (16.7) | |
| History of Medication (%) | Corticosteroid | 17(47.2) |
| Thiopurine | 12 (33.3) | |
| GMAA | 10 (27.8) | |
| Tacrolimus | 8 (22.2) | |
| Anti TNF-α agent | 10 (27.8) | |
| Duration of Medication (months) (Median)* | Mesalazine | 20.8 (0.5-247.2) |
| Corticosteroid | 11.7 (3.1-48.8) | |
| Thiopurine | 11.2 (1.8-205.7) | |
| GMAA | 2.1 (0.9-17.6) | |
| Tacrolimus | 2.1 (0.3-17.2) | |
| Anti TNF-α agent | 16.5 (0.3-61.0) |
*The median duration of medication in UC patients who had a history of treatment with mesalazine, corticosteroid, thiopurine, GMAA, tacrolimus and anti TNF-α agent, respectively.
CRP, C-reactive protein; SASP, Salazosulfapyridine; GMAA, Granulocyte monocyte adsorption apheresis; TNF, tumor necrosis factor.